general
Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022
SHANGHAI and HONG KONG, Sept. 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies,...
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Tokyo court grants legal protection to human voices in AI clone case
ABC News
Medevac helicopter carrying 5 crashes off California coast, killing 2
ABC News
Egg prices have tumbled since Trump returned to office. Here's why
NPR
Along U.S. Route 1, Maine voters worry about heating oil, gas and Canadian tariffs
NPR
Trade tensions mean fewer Canadians flocking to South Florida
NPR